| Ticker |
VTGN
|
| CIK | 0001411685 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080 |
| Website | vistagen.com |
| Phone | 650-577-3600 |
| CEO | Shawn K. Singh |
| Employees | 40 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayVistagen Therapeutics, Inc. (NASDAQ:VTGN) is among the best growth stocks to invest in for the next 5 years. Analysts at Stifel reiterated their Buy rating on Vistagen Therapeutics, Inc. (NASDAQ:VTGN) with an unchanged price target of $12.00 post the company’s fiscal 2025 announcement. Earlier in the current quarter, the management announced that while the PAL-3 […] Vistagen Appoints Elissa Cote as Chief Corporate Development OfficerSOUTH SAN FRANCISCO, Calif., June 25, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform toward potential commercial launc Vistagen Therapeutics Full Year 2025 Earnings: EPS Beats Expectations, Revenues LagVistagen Therapeutics ( NASDAQ:VTGN ) Full Year 2025 Results Key Financial Results Net loss: US$51.4m (loss widened by... Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...Despite increased R&D costs and net loss, Vistagen Therapeutics Inc (VTGN) remains focused on advancing its promising clinical-stage product candidates. Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif., June 17, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. |
